Simplify Asset Management Inc. Acquires Shares of 337,662 Inventiva S.A. Sponsored ADR $IVA

Simplify Asset Management Inc. acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 337,662 shares of the company’s stock, valued at approximately $1,570,000. Simplify Asset Management Inc. owned about 0.23% of Inventiva as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of IVA. Creative Planning bought a new position in Inventiva in the 2nd quarter valued at $32,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after acquiring an additional 9,212 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Inventiva during the third quarter worth $649,000. NewEdge Advisors LLC bought a new stake in shares of Inventiva during the third quarter worth $116,000. Finally, UBS Group AG raised its position in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after acquiring an additional 2,634,580 shares during the last quarter. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

NASDAQ:IVA opened at $5.07 on Monday. Inventiva S.A. Sponsored ADR has a 1 year low of $2.85 and a 1 year high of $7.98. The stock has a 50-day moving average price of $5.52 and a two-hundred day moving average price of $5.36.

Inventiva (NASDAQ:IVA) last posted its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million during the quarter. Research analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IVA shares. Truist Financial started coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price for the company. Barclays started coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, HC Wainwright set a $24.00 target price on Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.